Safety Reporting Requirements and Safety Assessment for IND and BA/BE Studies

CDER’s Paul Gouge, JD, provides background on Investigational New Drug (IND) safety reporting and describes the new guidance entitled, “Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies.”
_______________________________ 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2021 Playlist -    • 2021 CDER Small Business and Industry...  
SBIA LinkedIn:   / cder-small-business-and-industry-assistance  
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter -   / fda_drug_info  
Email - [email protected]  
Phone - (301) 796-6707 I (866) 405-5367